FDA FAERS Adverse Event Reports

111000
Total Reports
60668
Serious Reports
108
Reporter Countries
Clear
25947008 Type 1
Non-Serious
ZEPBOUND
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/18/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Consumer
Literature Reference
--
Company Number
US-ELI_LILLY_AND_COMPANY-US202510011417
Authority Number
--
Sender Organization
ELI LILLY AND COMPANY
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
No
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
79.0 yr
Patient Age Group
Elderly
Patient Sex
Female
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (1)

Visual impairment (v28.1) Unknown

Drugs (1)

ZEPBOUND (TIRZEPATIDE) Suspect
Route: 065 | Dosage: 5 MG, UNKNOWN | Form: Solution for injection | Indication: Product used for unknown indication | Action: Unknown
Auth#: 215866 | Batch#: -- | Structured Dosage: 5.0 (unit: 003) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --

Clinical Narrative

--

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b59", "safetyreportid": "25947008", "authoritynumb": null, "companynumb": "US-ELI_LILLY_AND_COMPANY-US202510011417", "duplicate": null, "fulfillexpeditecriteria": 2, "occurcountry": "US", "patient": { "patientonsetage": 79.0, "patientonsetageunit": 801, "patientagegroup": 6, "patientweight": null, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Visual impairment", "reactionoutcome": 6 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "ZEPBOUND", "drugauthorizationnumb": "215866", "drugbatchnumb": null, "drugstructuredosagenumb": 5.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "5 MG, UNKNOWN", "drugdosageform": "Solution for injection", "drugadministrationroute": "065", "drugindication": "Product used for unknown indication", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "TIRZEPATIDE" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": null }, "primarysource": { "reportercountry": "US", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "ELI LILLY AND COMPANY" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25947009 Type 1
Non-Serious
OMVOH
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/17/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Consumer
Literature Reference
--
Company Number
US-ELI_LILLY_AND_COMPANY-US202510020712
Authority Number
--
Sender Organization
ELI LILLY AND COMPANY
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
No
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
--
Patient Age Group
--
Patient Sex
--
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (1)

Hepatic enzyme increased (v28.1) Recovered

Drugs (1)

OMVOH (MIRIKIZUMAB-MRKZ) Suspect
Route: 065 | Dosage: UNK UNK, UNKNOWN | Form: -- | Indication: Colitis ulcerative | Action: Withdrawn
Auth#: 761279 | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Yes
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250922

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b5a", "safetyreportid": "25947009", "authoritynumb": null, "companynumb": "US-ELI_LILLY_AND_COMPANY-US202510020712", "duplicate": null, "fulfillexpeditecriteria": 2, "occurcountry": "US", "patient": { "patientonsetage": null, "patientonsetageunit": null, "patientagegroup": null, "patientweight": null, "patientsex": null, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Hepatic enzyme increased", "reactionoutcome": 1 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "OMVOH", "drugauthorizationnumb": "761279", "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "UNK UNK, UNKNOWN", "drugdosageform": null, "drugadministrationroute": "065", "drugindication": "Colitis ulcerative", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 1, "actiondrug": 1, "activesubstance": { "activesubstancename": "MIRIKIZUMAB-MRKZ" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250922" }, "primarysource": { "reportercountry": "US", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "ELI LILLY AND COMPANY" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-17T00:00:00", "transmissiondateformat": "102" }
25947004 Type 1
Non-Serious
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI, Lantheus generator (+1 more)
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/18/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Pharmacist
Literature Reference
--
Company Number
US-CURIUM-2025000659
Authority Number
--
Sender Organization
CURIUM PHARMACEUTICALS
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
No
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
65.0 yr
Patient Age Group
--
Patient Sex
Male
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (3)

Scan myocardial perfusion abnormal (v28.1) Recovered
Drug ineffective (v28.1) Not Recovered
Product preparation error (v28.1) Recovered

Drugs (4)

TECHNETIUM TC-99M SESTAMIBI (TECHNETIUM TC-99M SESTAMIBI) Suspect
Route: 042 | Dosage: -- | Form: Kit for radiopharmaceutical preparation | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: 078098 | Batch#: 09225004 | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
TECHNETIUM TC-99M SESTAMIBI (TECHNETIUM TC-99M SESTAMIBI) Suspect
Route: 042 | Dosage: -- | Form: Kit for radiopharmaceutical preparation | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: 078098 | Batch#: 09225004 | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
Lantheus generator (--) Concomitant
Route: 042 | Dosage: -- | Form: -- | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: -- | Batch#: UNK | Structured Dosage: 9.0 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
Lantheus generator (--) Concomitant
Route: 042 | Dosage: -- | Form: -- | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: -- | Batch#: UNK | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250821

Report Duplicates (2)

CURIUM local reference: 9623
TW complaint reference: PR 241840

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b57", "safetyreportid": "25947004", "authoritynumb": null, "companynumb": "US-CURIUM-2025000659", "duplicate": 1, "fulfillexpeditecriteria": 2, "occurcountry": "US", "patient": { "patientonsetage": 65.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": null, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Scan myocardial perfusion abnormal", "reactionoutcome": 1 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Drug ineffective", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Product preparation error", "reactionoutcome": 1 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "TECHNETIUM TC-99M SESTAMIBI", "drugauthorizationnumb": "078098", "drugbatchnumb": "09225004", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": "Kit for radiopharmaceutical preparation", "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TECHNETIUM TC-99M SESTAMIBI" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "TECHNETIUM TC-99M SESTAMIBI", "drugauthorizationnumb": "078098", "drugbatchnumb": "09225004", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": "Kit for radiopharmaceutical preparation", "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TECHNETIUM TC-99M SESTAMIBI" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "Lantheus generator", "drugauthorizationnumb": null, "drugbatchnumb": "UNK", "drugstructuredosagenumb": 9.0, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": null, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "Lantheus generator", "drugauthorizationnumb": null, "drugbatchnumb": "UNK", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": null, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250821" }, "primarysource": { "reportercountry": "US", "qualification": 2, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "CURIUM local reference", "duplicatenumb": "9623" }, { "duplicatesource": "TW complaint reference", "duplicatenumb": "PR 241840" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "CURIUM PHARMACEUTICALS" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25947002 Type 1
Serious
OPDIVO, FLUOROURACIL, OXALIPLATIN
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/18/2026
Primary Source Country
EU
Occurrence Country
EU
Reporter Country
EU
Reporter Qualification
Physician
Literature Reference
--
Company Number
--
Authority Number
EU-AFSSAPS-PB2025001288
Sender Organization
BRISTOL-MYERS SQUIBB COMPANY
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
73.0 yr
Patient Age Group
Adult
Patient Sex
Female
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (2)

Troponin increased (v28.1) Not Recovered
Myocarditis (v28.1) Not Recovered

Drugs (3)

OPDIVO (NIVOLUMAB) Suspect
Route: -- | Dosage: -- | Form: -- | Indication: Oesophageal squamous cell carcinoma metastatic | Action: Unknown
Auth#: 125554 | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 06/30/2025 | End: 09/08/2025 | Duration: 70.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --
FLUOROURACIL (FLUOROURACIL) Concomitant
Route: -- | Dosage: -- | Form: -- | Indication: Oesophageal squamous cell carcinoma metastatic | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 06/30/2025 | End: 09/08/2025 | Duration: 70.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --
OXALIPLATIN (OXALIPLATIN) Concomitant
Route: -- | Dosage: -- | Form: -- | Indication: Oesophageal squamous cell carcinoma metastatic | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 06/30/2025 | End: 07/14/2025 | Duration: 14.0 day | Rechallenge: -- | Additional: Unknown
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250922

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b56", "safetyreportid": "25947002", "authoritynumb": "EU-AFSSAPS-PB2025001288", "companynumb": null, "duplicate": null, "fulfillexpeditecriteria": 1, "occurcountry": "EU", "patient": { "patientonsetage": 73.0, "patientonsetageunit": 801, "patientagegroup": 5, "patientweight": null, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Troponin increased", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Myocarditis", "reactionoutcome": 3 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "OPDIVO", "drugauthorizationnumb": "125554", "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": null, "drugindication": "Oesophageal squamous cell carcinoma metastatic", "drugstartdateformat": "102", "drugstartdate": "2025-06-30T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-08T00:00:00", "drugtreatmentduration": 70.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "NIVOLUMAB" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "FLUOROURACIL", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": null, "drugindication": "Oesophageal squamous cell carcinoma metastatic", "drugstartdateformat": "102", "drugstartdate": "2025-06-30T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-09-08T00:00:00", "drugtreatmentduration": 70.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "FLUOROURACIL" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "OXALIPLATIN", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": null, "drugindication": "Oesophageal squamous cell carcinoma metastatic", "drugstartdateformat": "102", "drugstartdate": "2025-06-30T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-07-14T00:00:00", "drugtreatmentduration": 14.0, "drugtreatmentdurationunit": 804, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "OXALIPLATIN" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250922" }, "primarysource": { "reportercountry": "EU", "qualification": 1, "literaturereference": null }, "primarysourcecountry": "EU", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "BRISTOL-MYERS SQUIBB COMPANY" }, "serious": 1, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25947001 Type 1
Non-Serious
LEQVIO, ROSUVASTATIN
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/17/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Consumer
Literature Reference
--
Company Number
US-SANDOZ-SDZ2025US077742
Authority Number
--
Sender Organization
SANDOZ
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
--
Patient Age Group
--
Patient Sex
Female
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (3)

Pain in extremity (v28.1) Unknown
Urinary tract infection (v28.1) Unknown
Myalgia (v28.1) Unknown

Drugs (2)

LEQVIO (INCLISIRAN SODIUM) Suspect
Route: 058 | Dosage: UNK | Form: Solution for injection | Indication: Product used for unknown indication | Action: Unknown
Auth#: -- | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --
ROSUVASTATIN (ROSUVASTATIN) Suspect
Route: 065 | Dosage: UNK | Form: Unknown | Indication: Product used for unknown indication | Action: Unknown
Auth#: 079171 | Batch#: -- | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: -- | Additional: Unknown
Recurrences: --

Clinical Narrative

--

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b52", "safetyreportid": "25947001", "authoritynumb": null, "companynumb": "US-SANDOZ-SDZ2025US077742", "duplicate": null, "fulfillexpeditecriteria": 1, "occurcountry": "US", "patient": { "patientonsetage": null, "patientonsetageunit": null, "patientagegroup": null, "patientweight": null, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Pain in extremity", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Urinary tract infection", "reactionoutcome": 6 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Myalgia", "reactionoutcome": 6 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "LEQVIO", "drugauthorizationnumb": null, "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "UNK", "drugdosageform": "Solution for injection", "drugadministrationroute": "058", "drugindication": "Product used for unknown indication", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "INCLISIRAN SODIUM" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "ROSUVASTATIN", "drugauthorizationnumb": "079171", "drugbatchnumb": null, "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": "UNK", "drugdosageform": "Unknown", "drugadministrationroute": "065", "drugindication": "Product used for unknown indication", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "ROSUVASTATIN" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": null }, "primarysource": { "reportercountry": "US", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "SANDOZ" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-17T00:00:00", "transmissiondateformat": "102" }
25946999 Type 1
Non-Serious
TECHNETIUM TC-99M SESTAMIBI, Lantheus generator
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/19/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Pharmacist
Literature Reference
--
Company Number
US-CURIUM-2025000656
Authority Number
--
Sender Organization
CURIUM PHARMACEUTICALS
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
No
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
55.0 yr
Patient Age Group
--
Patient Sex
Female
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (4)

Scan myocardial perfusion abnormal (v28.1) Not Recovered
Drug ineffective (v28.1) Not Recovered
Product preparation error (v28.1) Recovered
Inappropriate schedule of product administration (v28.1) Recovered

Drugs (2)

TECHNETIUM TC-99M SESTAMIBI (TECHNETIUM TC-99M SESTAMIBI) Suspect
Route: 042 | Dosage: -- | Form: Kit for radiopharmaceutical preparation | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: 078098 | Batch#: 09225004 | Structured Dosage: 9.3 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
Lantheus generator (--) Concomitant
Route: 042 | Dosage: -- | Form: -- | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: -- | Batch#: UNK | Structured Dosage: 9.3 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250821

Report Duplicates (2)

CURIUM local reference: 9586
TW complaint reference: PR 241840

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b51", "safetyreportid": "25946999", "authoritynumb": null, "companynumb": "US-CURIUM-2025000656", "duplicate": 1, "fulfillexpeditecriteria": 2, "occurcountry": "US", "patient": { "patientonsetage": 55.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": null, "patientsex": 2, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Scan myocardial perfusion abnormal", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Drug ineffective", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Product preparation error", "reactionoutcome": 1 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Inappropriate schedule of product administration", "reactionoutcome": 1 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "TECHNETIUM TC-99M SESTAMIBI", "drugauthorizationnumb": "078098", "drugbatchnumb": "09225004", "drugstructuredosagenumb": 9.3, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": "Kit for radiopharmaceutical preparation", "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TECHNETIUM TC-99M SESTAMIBI" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "Lantheus generator", "drugauthorizationnumb": null, "drugbatchnumb": "UNK", "drugstructuredosagenumb": 9.3, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": null, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250821" }, "primarysource": { "reportercountry": "US", "qualification": 2, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "CURIUM local reference", "duplicatenumb": "9586" }, { "duplicatesource": "TW complaint reference", "duplicatenumb": "PR 241840" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "CURIUM PHARMACEUTICALS" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-19T00:00:00", "transmissiondateformat": "102" }
25946996 Type 1
Non-Serious
TECHNETIUM TC-99M SESTAMIBI, Lantheus generator
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/18/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Pharmacist
Literature Reference
--
Company Number
US-CURIUM-2025000655
Authority Number
--
Sender Organization
CURIUM PHARMACEUTICALS
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
No
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
--
Patient Age Group
--
Patient Sex
--
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (3)

Scan myocardial perfusion abnormal (v28.1) Not Recovered
Drug ineffective (v28.1) Not Recovered
Product preparation error (v28.1) Recovered

Drugs (2)

TECHNETIUM TC-99M SESTAMIBI (TECHNETIUM TC-99M SESTAMIBI) Suspect
Route: 042 | Dosage: -- | Form: Kit for radiopharmaceutical preparation | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: 078098 | Batch#: 09225004 | Structured Dosage: 10.0 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
Lantheus generator (--) Concomitant
Route: 042 | Dosage: -- | Form: -- | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: -- | Batch#: UNK | Structured Dosage: 10.0 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250821

Report Duplicates (2)

CURIUM local reference: 9585
TW complaint reference: PR 241840

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b4f", "safetyreportid": "25946996", "authoritynumb": null, "companynumb": "US-CURIUM-2025000655", "duplicate": 1, "fulfillexpeditecriteria": 2, "occurcountry": "US", "patient": { "patientonsetage": null, "patientonsetageunit": null, "patientagegroup": null, "patientweight": null, "patientsex": null, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Scan myocardial perfusion abnormal", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Drug ineffective", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Product preparation error", "reactionoutcome": 1 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "TECHNETIUM TC-99M SESTAMIBI", "drugauthorizationnumb": "078098", "drugbatchnumb": "09225004", "drugstructuredosagenumb": 10.0, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": "Kit for radiopharmaceutical preparation", "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TECHNETIUM TC-99M SESTAMIBI" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "Lantheus generator", "drugauthorizationnumb": null, "drugbatchnumb": "UNK", "drugstructuredosagenumb": 10.0, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": null, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250821" }, "primarysource": { "reportercountry": "US", "qualification": 2, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "CURIUM local reference", "duplicatenumb": "9585" }, { "duplicatesource": "TW complaint reference", "duplicatenumb": "PR 241840" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "CURIUM PHARMACEUTICALS" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25946994 Type 1
Non-Serious
REVLIMID
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/18/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Consumer
Literature Reference
--
Company Number
US-BRISTOL-MYERS SQUIBB COMPANY-2025-143634
Authority Number
--
Sender Organization
BRISTOL-MYERS SQUIBB COMPANY
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
No
Duplicate
--
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
80.0 yr
Patient Age Group
Elderly
Patient Sex
Male
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (1)

Product dose omission issue (v28.1) Unknown

Drugs (1)

REVLIMID (LENALIDOMIDE) Suspect
Route: -- | Dosage: -- | Form: Capsule | Indication: Product used for unknown indication | Action: Dose Not Changed
Auth#: 021880 | Batch#: -- | Structured Dosage: 10.0 (unit: 003) | Separate Dosage#: 1.0 | Interval: 2.0 day | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: Unknown | Additional: --
Recurrences: --

Clinical Narrative

--

Report Duplicates (0)

--

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b4a", "safetyreportid": "25946994", "authoritynumb": null, "companynumb": "US-BRISTOL-MYERS SQUIBB COMPANY-2025-143634", "duplicate": null, "fulfillexpeditecriteria": 2, "occurcountry": "US", "patient": { "patientonsetage": 80.0, "patientonsetageunit": 801, "patientagegroup": 6, "patientweight": null, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Product dose omission issue", "reactionoutcome": 6 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "REVLIMID", "drugauthorizationnumb": "021880", "drugbatchnumb": null, "drugstructuredosagenumb": 10.0, "drugstructuredosageunit": "003", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": 2.0, "drugintervaldosagedefinition": 804, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": "Capsule", "drugadministrationroute": null, "drugindication": "Product used for unknown indication", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": 3, "drugadditional": null, "actiondrug": 4, "activesubstance": { "activesubstancename": "LENALIDOMIDE" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": null }, "primarysource": { "reportercountry": "US", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "BRISTOL-MYERS SQUIBB COMPANY" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25946995 Type 1
Non-Serious
TECHNETIUM TC-99M SESTAMIBI, TECHNETIUM TC-99M SESTAMIBI, Lantheus generator (+1 more)
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/18/2026
Primary Source Country
US
Occurrence Country
US
Reporter Country
US
Reporter Qualification
Pharmacist
Literature Reference
--
Company Number
US-CURIUM-2025000657
Authority Number
--
Sender Organization
CURIUM PHARMACEUTICALS
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
No
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
54.0 yr
Patient Age Group
--
Patient Sex
--
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (4)

Scan myocardial perfusion abnormal (v28.1) Not Recovered
Drug ineffective (v28.1) Not Recovered
Product preparation error (v28.1) Recovered
Inappropriate schedule of product administration (v28.1) Recovered

Drugs (4)

TECHNETIUM TC-99M SESTAMIBI (TECHNETIUM TC-99M SESTAMIBI) Suspect
Route: 042 | Dosage: -- | Form: Kit for radiopharmaceutical preparation | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: 078098 | Batch#: 09225004 | Structured Dosage: 9.0 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
TECHNETIUM TC-99M SESTAMIBI (TECHNETIUM TC-99M SESTAMIBI) Suspect
Route: 042 | Dosage: -- | Form: Kit for radiopharmaceutical preparation | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: 078098 | Batch#: 09225004 | Structured Dosage: 31.0 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
Lantheus generator (--) Concomitant
Route: 042 | Dosage: -- | Form: -- | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: -- | Batch#: UNK | Structured Dosage: 9.0 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --
Lantheus generator (--) Concomitant
Route: 042 | Dosage: -- | Form: -- | Indication: Scan myocardial perfusion | Action: Not Applicable
Auth#: -- | Batch#: UNK | Structured Dosage: 31.0 (unit: 019) | Separate Dosage#: 1.0 | Interval: -- -- | Cumulative: -- (unit: --)
Start: 08/21/2025 | End: 08/21/2025 | Duration: -- -- | Rechallenge: -- | Additional: 4
Recurrences: --

Clinical Narrative

CASE EVENT DATE: 20250821

Report Duplicates (2)

CURIUM local reference: 9587
TW complaint reference: PR 241840

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b4c", "safetyreportid": "25946995", "authoritynumb": null, "companynumb": "US-CURIUM-2025000657", "duplicate": 1, "fulfillexpeditecriteria": 2, "occurcountry": "US", "patient": { "patientonsetage": 54.0, "patientonsetageunit": 801, "patientagegroup": null, "patientweight": null, "patientsex": null, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Scan myocardial perfusion abnormal", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Drug ineffective", "reactionoutcome": 3 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Product preparation error", "reactionoutcome": 1 }, { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Inappropriate schedule of product administration", "reactionoutcome": 1 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "TECHNETIUM TC-99M SESTAMIBI", "drugauthorizationnumb": "078098", "drugbatchnumb": "09225004", "drugstructuredosagenumb": 9.0, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": "Kit for radiopharmaceutical preparation", "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TECHNETIUM TC-99M SESTAMIBI" }, "drugrecurrence": [] }, { "drugcharacterization": 1, "medicinalproduct": "TECHNETIUM TC-99M SESTAMIBI", "drugauthorizationnumb": "078098", "drugbatchnumb": "09225004", "drugstructuredosagenumb": 31.0, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": "Kit for radiopharmaceutical preparation", "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": { "activesubstancename": "TECHNETIUM TC-99M SESTAMIBI" }, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "Lantheus generator", "drugauthorizationnumb": null, "drugbatchnumb": "UNK", "drugstructuredosagenumb": 9.0, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": null, "drugrecurrence": [] }, { "drugcharacterization": 2, "medicinalproduct": "Lantheus generator", "drugauthorizationnumb": null, "drugbatchnumb": "UNK", "drugstructuredosagenumb": 31.0, "drugstructuredosageunit": "019", "drugseparatedosagenumb": 1.0, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": "042", "drugindication": "Scan myocardial perfusion", "drugstartdateformat": "102", "drugstartdate": "2025-08-21T00:00:00", "drugenddateformat": "102", "drugenddate": "2025-08-21T00:00:00", "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": null, "drugadditional": 4, "actiondrug": 6, "activesubstance": null, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": "CASE EVENT DATE: 20250821" }, "primarysource": { "reportercountry": "US", "qualification": 2, "literaturereference": null }, "primarysourcecountry": "US", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "CURIUM local reference", "duplicatenumb": "9587" }, { "duplicatesource": "TW complaint reference", "duplicatenumb": "PR 241840" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "CURIUM PHARMACEUTICALS" }, "serious": 2, "seriousnesscongenitalanomali": 2, "seriousnessdeath": 2, "seriousnessdisabling": 2, "seriousnesshospitalization": 2, "seriousnesslifethreatening": 2, "seriousnessother": 2, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }
25946991 Type 1
Serious
ZOLEDRONIC ACID
Report Version
1
Receive Date
10/22/2025
Receipt Date
10/22/2025
Transmission Date
01/18/2026
Primary Source Country
CA
Occurrence Country
CA
Reporter Country
CA
Reporter Qualification
Consumer
Literature Reference
--
Company Number
--
Authority Number
CA-DRL-USA-CAN/2025/10/015740
Sender Organization
DR REDDYS
Sender Type
6
Receiver Organization
FDA
Receiver Type
6
Expedite Criteria
Yes
Duplicate
1
FAERS Quarter
2025Q4
Source File
1_ADR25Q4.xml
Patient Age
--
Patient Age Group
--
Patient Sex
Male
Patient Weight
--

Seriousness Details

Death Hospitalization Life-Threatening Disabling Congenital Anomaly Other Serious

Reactions (1)

Neoplasm malignant (v28.1) Unknown

Drugs (1)

ZOLEDRONIC ACID (ZOLEDRONIC ACID) Suspect
Route: 065 | Dosage: -- | Form: -- | Indication: Product used for unknown indication | Action: Unknown
Auth#: 091186 | Batch#: Unknown | Structured Dosage: -- (unit: --) | Separate Dosage#: -- | Interval: -- -- | Cumulative: -- (unit: --)
Start: -- | End: -- | Duration: -- -- | Rechallenge: Unknown | Additional: Unknown
Recurrences: --

Clinical Narrative

--

Report Duplicates (2)

Duplicate: SDZ2025CA027953
Adverse Reaction Report Number: E2B_08034268

Raw JSON (click to expand)

{ "_id": "69d4356e3b3830196fa53b4b", "safetyreportid": "25946991", "authoritynumb": "CA-DRL-USA-CAN/2025/10/015740", "companynumb": null, "duplicate": 1, "fulfillexpeditecriteria": 1, "occurcountry": "CA", "patient": { "patientonsetage": null, "patientonsetageunit": null, "patientagegroup": null, "patientweight": null, "patientsex": 1, "reaction": [ { "reactionmeddraversionpt": "28.1", "reactionmeddrapt": "Neoplasm malignant", "reactionoutcome": 6 } ], "drug": [ { "drugcharacterization": 1, "medicinalproduct": "ZOLEDRONIC ACID", "drugauthorizationnumb": "091186", "drugbatchnumb": "Unknown", "drugstructuredosagenumb": null, "drugstructuredosageunit": null, "drugseparatedosagenumb": null, "drugintervaldosageunitnumb": null, "drugintervaldosagedefinition": null, "drugcumulativedosagenumb": null, "drugcumulativedosageunit": null, "drugdosagetext": null, "drugdosageform": null, "drugadministrationroute": "065", "drugindication": "Product used for unknown indication", "drugstartdateformat": null, "drugstartdate": null, "drugenddateformat": null, "drugenddate": null, "drugtreatmentduration": null, "drugtreatmentdurationunit": null, "drugrecurreadministration": 3, "drugadditional": 3, "actiondrug": 5, "activesubstance": { "activesubstancename": "ZOLEDRONIC ACID" }, "drugrecurrence": [] } ], "summary_narrativeincludeclinical": null }, "primarysource": { "reportercountry": "CA", "qualification": 5, "literaturereference": null }, "primarysourcecountry": "CA", "quarter": "2025Q4", "receiptdate": "2025-10-22T00:00:00", "receiptdateformat": "102", "receivedate": "2025-10-22T00:00:00", "receivedateformat": "102", "receiver": { "receivertype": 6, "receiverorganization": "FDA" }, "reportduplicate": [ { "duplicatesource": "Duplicate", "duplicatenumb": "SDZ2025CA027953" }, { "duplicatesource": "Adverse Reaction Report Number", "duplicatenumb": "E2B_08034268" } ], "reporttype": 1, "safetyreportversion": 1, "sender": { "sendertype": 6, "senderorganization": "DR REDDYS" }, "serious": 1, "seriousnesscongenitalanomali": null, "seriousnessdeath": null, "seriousnessdisabling": null, "seriousnesshospitalization": null, "seriousnesslifethreatening": null, "seriousnessother": 1, "source_file": "1_ADR25Q4.xml", "transmissiondate": "2026-01-18T00:00:00", "transmissiondateformat": "102" }